As has now become known, there is a new contract for Smart4Diagnostics, which will launch its insolvency Venture Targeter 3 AB, a subsidiary of the Swedish venture capital firm Katalysen Ventures AB, backed by a group of investors from Sweden, the United Kingdom, and the United States, has acquired the business retroactively to March 1 and also taken over the entire workforce. Insolvency administrator Elske Fehl-Weileder von Schultze & Braun says:
"I'm very pleased that the restructuring and reorganization has been successful. Smart4Diagnostics can now expand its core competence in the field of digital tracking of laboratory samples, so-called pre-analytics, and take the application to the next level."
She continues:
“The fact that there is now a future perspective for the world’s first digital and automated quality assurance for human blood samples was largely due to the great commitment of the employees, who strongly identify with the company and the solution that they largely developed themselves,”
New quality standard for medical diagnostics
Smart4Diagnostics was founded in 2018 by Julia Flötotto, Hans Maria Heÿn, Malte Dancker and Timo Böge for very practical reasons, such as Timo Böge in an interview with Munich Startup reported:
"Our founding team didn't emerge from academia with a technology; we came with a practical problem. In our previous careers in the laboratory and hospital, we identified a quality problem in the handling of blood samples, but hadn't found a practical and contemporary solution on the market. Therefore, we decided to develop a solution."
With the Munich-based startup's Smart.Safe.Samples™ digital system, (human) blood samples can be digitally and automatically tracked from their collection from patients in the doctor's office or clinic to their final analysis in the laboratory. Integration into the workflows of all involved parties is intended to enable a new quality standard for medical diagnostics and a complete data chain for every human blood sample.
Positive outlook for 2024
Robin Nagel of Smart4Diagnostics, who will be managing the business operations in the future, is convinced of the investor solution:
"Our partners believe in Smart4Diagnostics' solution, just like we do, and have supported us over the past few months. With the investor solution now found, Smart4Diagnostics is positioned to not only look ahead to 2024 with optimism, but also to make investments to further develop the software."
Peter Almberg, CEO of Katalysen Ventures AB, explains his decision to invest in the Munich-based company as follows:
"What convinced us about Smart4Diagnostics is the enormous market potential for digital pre-analytical solutions. We want to further develop this together with the team and take it to the next level."
Smart4Diagnostics says it collaborates with around 15 laboratories. The Munich-based startup is also participating in various international tenders with partners from the medical sector, with a volume of several million euros, although decisions are not expected until later this year.
